US FDA Finds Phenylephrine Ineffective As Nasal Decongestant, Looks At Removing From Monograph
Agency Asks For NDAC Input On 'Unintended Consequences' On Consumers, Industry
Executive Summary
Phenylephrine doesn’t meet efficacy bar within “generally regarded as safe and effective” standard for OTC monograph drugs, agency says in briefing prepared for NDAC meeting on 11-12 September. FDA say it is “concerned about avoiding potential unintended consequences with regard to changing the GRASE status of oral PE.”
You may also be interested in...
Message Clear For Xylitol Nasal Spray Firm Xlear: ‘Capitalize’ On FDA’s Oral Phenylephrine Doubts
“Pharmaceuticals have their place, and many do wonderful things for health, but the science of nasal hygiene is clear,” says marketing director Joel Melton.
Fast Start To Oral Phenylephrine Efficacy Complaints As US FDA Considers 'Any Action'
Two days after FDA advisory panel’s meeting to discuss whether oral phenylephrine is effective for nasal congestion, complaints filed in federal court in multiple states alleging manufacturers knowingly misled public about ingredient’s efficacy. FDA’s potential response to NDAC’S finding wouldn’t come as soon.
Oral Phenylephrine Study Results Spell Nasal Decongestion Failure To Critics, GRASE To Industry
FDA officials, joined by supporters of deeming ingredient non-GRASE, note problems with research referenced in initial GRASE designation. CHPA explained studies used to support GRASE designation for phenylephrine hydrochloride in 1976, for addition of bitartrate salt in 2006 and other results published since show ingredient’s efficacy for nasal decongestion.